The study on higher doses of oral semaglutide. It appears that the study, conducted by John Buse, MD, PhD, and his team, found that higher doses of oral semaglutide (25 mg and 50 mg) were more effective in lowering blood sugar levels and promoting weight loss compared to the lower dose of 14 mg. The study, published in The Lancet, involved 1,606 participants with an average age of 58.2 years and focused on evaluating the efficacy of different dosages of semaglutide over a 52-week period.
The results showed that participants who received the 25 mg and 50 mg doses of oral semaglutide were more likely to achieve the target A1C level of less than 7%, which is considered healthy according to the American Diabetes Association. Additionally, the higher doses of semaglutide resulted in greater weight loss, with an average loss of 17.5 pounds for those taking 50 mg, compared to 14.8 pounds for the 25 mg group and 10 pounds for the 14 mg group.
It’s worth noting that semaglutide, as a glucagon-like peptide-1 (GLP-1) receptor agonist, works by reducing blood sugar levels and suppressing appetite, thereby aiding in weight loss. However, some common side effects reported in the study included nausea, vomiting, diarrhea, and constipation, particularly among those taking the higher doses of semaglutide (25 mg and 50 mg).
These findings contribute to the growing body of evidence supporting the use of GLP-1 receptor agonists, including semaglutide, in the treatment of diabetes and obesity. However, it’s important to consult with healthcare professionals for personalized advice and to stay updated on the latest research developments in this field.
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.